Treatment for defined patients with MDR-TB and XDR-TB including bedaquiline and delamanid

Document first published:
Page updated:
Topic:
Publication type:

NHS England will commission treatment for defined patients with MDR-TB and XDR-TB including bedaquiline and delamanid in accordance with the criteria outlined in this document.

Document

Clinical Commissioning Policy: Treatment for defined patients with MDR-TB and XDR-TB including bedaquiline and delamanid

Clinical Commissioning Policy: Treatment for defined patients with MDR-TB and XDR-TB including bedaquiline and delamanid

  • PDF
  • 300 KB
  • 35 pages

Summary

Updated December 2020.

Document

Clinical Panel Report: Treatment for defined patients with MDR-TB and XDR-TB including bedaquiline and delamanid

Clinical Panel Report: Treatment for defined patients with MDR-TB and XDR-TB including bedaquiline and delamanid

  • PDF
  • 76 KB

Document

CPAG Summary Report: Treatment for defined patients with MDR-TB and XDR-TB including bedaquiline and delamanid

CPAG Summary Report: Treatment for defined patients with MDR-TB and XDR-TB including bedaquiline and delamanid

  • PDF
  • 176 KB

Document

Evidence Review Adults: Treatment for defined patients with MDR-TB and XDR-TB including bedaquiline and delamanid

Evidence Review Adults: Treatment for defined patients with MDR-TB and XDR-TB including bedaquiline and delamanid

  • PDF
  • 506 KB

Document

Evidence Review Children: Treatment for defined patients with MDR-TB and XDR-TB including bedaquiline and delamanid

Evidence Review Children: Treatment for defined patients with MDR-TB and XDR-TB including bedaquiline and delamanid

  • PDF
  • 376 KB

Document

Stakeholder Engagement Report: Treatment for defined patients with MDR-TB and XDR-TB including bedaquiline and delamanid

Stakeholder Engagement Report: Treatment for defined patients with MDR-TB and XDR-TB including bedaquiline and delamanid

  • PDF
  • 35 KB